Illumina vs 23andMe Which Is More Profitable?

Illumina and 23andMe are two prominent companies in the genomics industry, each offering unique opportunities for investors looking to capitalize on the growing interest in personalized healthcare and genetic testing. Illumina, a leader in DNA sequencing technology, provides tools and services to researchers and clinical labs worldwide, while 23andMe offers direct-to-consumer genetic testing kits. Both companies have seen significant growth in recent years, but their stocks have faced different challenges and opportunities in the competitive genomics market.

Illumina or 23andMe?

When comparing Illumina and 23andMe, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Illumina and 23andMe.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Illumina has a dividend yield of -%, while 23andMe has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Illumina reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, 23andMe reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Illumina P/E ratio at -14.69 and 23andMe's P/E ratio at -0.14. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Illumina P/B ratio is 10.96 while 23andMe's P/B ratio is 0.83.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Illumina has seen a 5-year revenue growth of 0.26%, while 23andMe's is -0.98%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Illumina's ROE at -42.15% and 23andMe's ROE at -303.43%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $144.92 for Illumina and $3.27 for 23andMe. Over the past year, Illumina's prices ranged from $97.36 to $156.66, with a yearly change of 60.90%. 23andMe's prices fluctuated between $2.65 and $20.40, with a yearly change of 668.36%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.